Zevra Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Zevra Therapeutics

04/05/2024 02:25

* Zevra Therapeutics Inc  ZVRA.OQ   ZVRA.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 7 for
the period ending March 31 2024
    * The Celebration Florida-based  company is expected to
report a
30.7% increase in revenue to $3.764 million from $2.88 million a
year ago, according to the mean estimate from 6 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Zevra Therapeutics Inc
is for
a loss of 48 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 4.2%
in the last three months. ​
    * Wall Street's median 12-month price target for Zevra
Therapeutics Inc is $18.50​, above​ its last closing price
of $4.81. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.19       -0.27      -0.40     Missed  -49.1
 Sep. 30 2023  -0.30       -0.30      -0.40     Missed  -34.5
 Jun. 30 2023  -0.37       -0.34      -0.15     Beat    56.3​
 Mar. 31 2023  -0.24       -0.23      -0.34     Missed  -46.2
 ​​Dec.        -0.17       -0.17      -0.26     Missed  -50
 31 2022                                                
 Sep. 30 2022  -0.13       -0.13      -0.19     Missed  -46.2​
 Jun. 30 2022  -0.12       -0.12      -0.19     Missed  -58.3
 Mar. 31 2022  -0.05       -0.05      -0.05     Met     9.1
 This summary was machine generated May 4 at 01:25 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)